OM Form 4: Marc Nash sell-to-cover 243 shares for tax withholding
Rhea-AI Filing Summary
Marc Nash, SVP Operations and R&D and director of Outset Medical (OM), reported a non-discretionary sell-to-cover transaction on 08/15/2025. He sold 243 shares of Outset common stock at $12.88 per share to satisfy tax withholding related to the vesting of an aggregate 673 restricted stock units granted on March 15, 2023, July 24, 2023, and January 12, 2024. After the transaction, the reporting person beneficially owned 42,898 shares directly. The Form 4 was signed by John L. Brottem on behalf of Marc Nash on 08/18/2025.
This filing is a routine insider tax-withholding sale and the filer states it was not a discretionary trade.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine sell-to-cover of vested RSUs; no indication of discretionary insider selling.
The disclosed sale of 243 shares at $12.88 was executed solely to satisfy tax withholding on 673 vested RSUs from grants in 2023 and 2024. The report shows a direct beneficial ownership of 42,898 shares after the transaction, which suggests the insider retains substantial equity alignment with shareholders. There are no indications of additional open-market trading or a broader disposition program in this filing.
TL;DR: Transaction appears compliant and procedural; documentation includes required explanation and signature.
The Form 4 includes the required explanatory note that the sale was to cover tax withholding and includes a dated signature by an authorized filer. From a governance perspective, this is a routine disclosure fulfilling Section 16 reporting obligations and does not, by itself, raise red flags about disclosure practices or insider conduct.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 243 | $12.88 | $3K |
Footnotes (1)
- [object Object]